カテゴリー： 世界, 医療/バイオ, MarketsandMarkets

世界の再生医療市場（～2028年）：製品別（幹細胞（自己由来、同種異系）、免疫療法、遺伝子療法、ティッシュエンジニアリング）、用途別（筋骨格系、がん、皮膚科、創傷治療、心血管疾患、眼疾患）

【英語タイトル】Regenerative Medicine Market by Product (Stem Cell [Autologous, Allogenic], Immunotherapy, Gene Therapy, Tissue Engineering), Application (Musculoskeletal, Cancer, Dermatology, Wound care, Cardiovascular Diseases, Eye Disorders) - Global Forecast to 2028

MarketsandMarketsが出版した調査資料（BT4419-24）・商品コード：BT4419-24
・発行会社（調査会社）：MarketsandMarkets
・発行日：2024年1月26日
・ページ数：293
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥752,400見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥1,010,800見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥1,238,800見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

“世界の再生医療市場は、2023年の160億米ドルから2028年には490億米ドルに達すると予測され、2023年から2028年の予測期間中の年平均成長率は25.1％”新たな治療領域における広範な展望や、主要な市場参入企業による共同研究や提携などの要因が、今後数年間で市場を押し上げると予測されます。さらに、個別化医療への注目の高まりと再生医療規制認可の増加は、有利な市場成長をもたらすでしょう。しかし、長期的なデータの欠如、倫理的・法的な懸念、治療費の高騰が市場を制限すると予測されています。

“再生医療市場では細胞治療分野が圧倒的シェアを保持”
製品に基づき、世界の再生医療市場は、遺伝子治療、細胞治療（幹細胞治療（細胞移植、幹細胞治療製品（自家療法、同種療法）細胞ベースの免疫療法製品）、組織工学製品に区分されます。幹細胞治療の人気の高まりは、細胞治療市場の拡大を促進すると予想されます。

“2022年の治療分野別では筋骨格系疾患分野が最大シェア”
治療領域に基づき、再生医療市場は、腫瘍学、筋骨格系障害、神経学、眼科、皮膚科＆創傷治療、心血管疾患、およびその他の用途にセグメント化されます。これは、整形外科疾患の罹患率が増加していること、および筋骨格系の再生研究に対する関心が高まっていることに起因しています。

“アジア太平洋はより速いペースで成長する可能性が高い”
再生医療市場は、北米、ヨーロッパ、アジア太平洋、中南米、中東、アフリカに区分されます。アジア太平洋は予測期間中に大きなCAGRで成長すると予測されています。慢性疾患の負担が大きいこと、一人当たり所得が増加していること、新技術に対する需要が高まっていることなどが、同地域の再生医療市場の成長を支えるものと期待されています。

本レポートのために実施した一次インタビューは以下のように分類できます：

- 回答者別 供給側80％、需要側20％
- 指定（供給側）別 管理職：45％、CXO・取締役：30％、経営幹部：25％
- 地域別 北米：55％、ヨーロッパ：10％、アジア太平洋：20％、中南米：10％、中東・アフリカ：5％

レポート掲載企業リストは以下の通りです：

• Novartis AG (Switzerland)
• Biogen, Inc. (US)
• Sarepta Therapeutics, Inc. (US)
• Gilead Sciences, Inc. (US)
• Amgen Inc. (US)
• Smith+Nephew (UK)
• MEDIPOST Co., Ltd. (Korea)
• JCR Pharmaceuticals Co., Ltd. (Japan)
• Takeda Pharmaceutical Company Limited (Japan)
• CORESTEM, Inc (South Korea)
• Vericel Corporation (US)
• MIMEDX Group, Inc. (US)
• Organogenesis Inc. (US)
• Medtronic (Ireland)
• Bristol-Myers Squibb Company (US)
• Orthocell Ltd. (Australia)
• Mesoblast Ltd. (Australia)
• BioRestorative Therapies, Inc. (US)
• Pluristem Therapeutics Inc. (US)
• TEGOSCIENCE (South Korea)
• ANTEROGEN.CO.,LTD. (South Korea)
• Bluebird bio, Inc. (US)
• Stempeutics Research Pvt Ltd. (India)
• Sibiono GeneTech Co. Ltd. (China)
• Aspect Biosystems Ltd. (Canada)
• Athersys, Inc. (US)

調査範囲

この調査レポートは、再生医療市場の詳細な状況を掲載しています。製品、治療分野、地域などの異なるセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの会社概要、最近の動向、主要市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点

本レポートは、再生医療市場全体とそのサブセグメントにおける収益数の最も近い概算値を提供することで、市場リーダー/新規参入者を支援します。また、利害関係者が競争状況をよりよく理解し、より多くの洞察を得ることで、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるのに役立ちます。本レポートは、関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、機会、および課題に関する情報を提供することを可能にします。

本レポートは、以下のポイントに関する洞察を提供します：

- 主な促進要因（個別化医療への注目の高まり、再生医療における規制承認の急上昇、主要市場プレイヤーによる共同研究やパートナーシップの増加、新たな治療領域におけるスコープの拡大）、阻害要因（長期データの欠如、倫理的・法的懸念、治療費の高騰）、機会（人工知能やビッグデータとの統合、3Dプリンティングの可能性の活用、臓器移植数の増加）、課題（様々な地域における有利な償還政策の欠如）が再生医療市場の成長に影響を及ぼしていることを分析します。
- 製品開発/イノベーション： 再生医療市場で新たに発売された製品に関する詳細な洞察を提供します。
- 市場開発： 有利な市場に関する包括的な情報 - 当レポートでは、様々な地域の再生医療市場を分析しています。
- 市場の多様化： 再生医療市場における新製品、未開拓の地域、最近の開発、投資に関する詳細な情報を記載しています。
- 競合評価： 再生医療市場におけるNovartis AG (Switzerland), Biogen, Inc. (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Amgen Inc. (US), Smith+Nephew (UK), MEDIPOST Co., Ltd. (Korea), JCR Pharmaceuticals Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan) and CORESTEM, Inc (South Korea)などの主要企業の市場ランキング、成長戦略、主要企業のサービス提供などの詳細な評価を提供しています。

1.　序論
2.　調査方法
3.　エグゼクティブサマリー
4.　プレミアムインサイト
5.　市場概要
6.　世界の再生医療市場規模：製品別
7.　世界の再生医療市場規模：治療部位別
8.　世界の再生医療市場規模：地域別
9.　競争状況
10.　企業情報
11.　付録

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1 INTRODUCTION 35
1.1 STUDY OBJECTIVES 35
1.2 MARKET DEFINITION 35
1.2.1 INCLUSIONS & EXCLUSIONS 36
1.3 MARKET SCOPE 36
1.3.1 MARKETS COVERED 36
1.3.2 YEARS CONSIDERED 37
1.3.3 CURRENCY CONSIDERED 37
1.4 RESEARCH LIMITATIONS 37
1.5 STAKEHOLDERS 38
1.6 SUMMARY OF CHANGES 38
1.7 IMPACT OF RECESSION ON REGENERATIVE MEDICINE MARKET 39
2 RESEARCH METHODOLOGY 40
2.1 RESEARCH DATA 40
FIGURE 1 RESEARCH DESIGN 40
2.1.1 SECONDARY DATA 41
2.1.2 PRIMARY DATA 42
FIGURE 2 BREAKDOWN OF PRIMARIES: REGENERATIVE MEDICINE MARKET 42
2.2 MARKET SIZE ESTIMATION 43
FIGURE 3 MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS: REGENERATIVE MEDICINE MARKET, 2022 43
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022 44
FIGURE 5 NOVARTIS AG: REVENUE SHARE ANALYSIS, 2022 44
FIGURE 6 PRODUCT-BASED REVENUE ANALYSIS, 2022 46
2.2.1 PRIMARY INSIGHTS 47
FIGURE 7 VALIDATION FROM PRIMARY EXPERTS 47
2.2.2 SEGMENT ASSESSMENT METHODOLOGY: REGENERATIVE MEDICINE MARKET 47
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 47
FIGURE 9 CAGR PROJECTIONS: REGENERATIVE MEDICINE MARKET 48
FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES IN REGENERATIVE MEDICINE MARKET 49
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 50
FIGURE 11 DATA TRIANGULATION METHODOLOGY 50
2.4 STUDY ASSUMPTIONS 51
2.5 RISK ANALYSIS 51
2.6 IMPACT OF RECESSION ON REGENERATIVE MEDICINE MARKET 52
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2024–2028 (% GROWTH) 52
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 53
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 53
3 EXECUTIVE SUMMARY 54
FIGURE 12 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 54
FIGURE 13 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION) 55
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF REGENERATIVE MEDICINE MARKET 56
4 PREMIUM INSIGHTS 57
4.1 REGENERATIVE MEDICINE MARKET OVERVIEW 57
FIGURE 15 FOCUS ON PERSONALISED MEDICINE TO DRIVE MARKET GROWTH 57
4.2 NORTH AMERICA: REGENERATIVE MEDICINE MARKET 58
FIGURE 16 CELL THERAPY TO COMMAND LARGEST SHARE OF NORTH AMERICAN REGENERATIVE MEDICINE MARKET 58
4.3 REGENERATIVE MEDICINE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59
FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
FIGURE 18 REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60
5.2.1 DRIVERS 61
5.2.1.1 Growing focus on personalized medicine 61
FIGURE 19 PERCENTAGE OF FDA APPROVALS FOR PERSONALIZED MEDICINE PRODUCTS (2018–2022) 61
5.2.1.2 Emerging applications in new therapeutic areas 62
TABLE 4 REGENERATIVE MEDICINE MARKET: EMERGING APPLICATIONS 63
5.2.1.3 Increasing collaborations and partnerships by major market players 64
5.2.1.4 Increasing regulatory approvals in regenerative medicine 65
TABLE 5 LIST OF KEY PRODUCT APPROVALS IN REGENERATIVE MEDICINE MARKET, 2021–2023 65
5.2.2 RESTRAINTS 66
5.2.2.1 Lack of long-term data 66
5.2.2.2 Ethical and legal concerns and high cost of treatments 66
5.2.3 OPPORTUNITIES 67
5.2.3.1 Harnessing the potential of 3D printing 67
5.2.3.2 Integration with artificial intelligence and big data 68
5.2.3.3 Growing number of organ transplants 68
5.2.4 CHALLENGES 69
5.2.4.1 Lack of favorable reimbursement policies across various regions 69
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 70
FIGURE 20 REVENUE SHIFT TOWARD REGENERATIVE MEDICINE COMPANIES 71
5.4 PRICING ANALYSIS 71
5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT 71
TABLE 6 REGENERATIVE MEDICINE PRICE TREND 71
5.5 SUPPLY CHAIN ANALYSIS 72
FIGURE 21 SUPPLY CHAIN ANALYSIS: REGENERATIVE MEDICINE MARKET 73
5.6 VALUE CHAIN ANALYSIS 73
FIGURE 22 VALUE CHAIN ANALYSIS: REGENERATIVE MEDICINE MARKET 74
5.7 ECOSYSTEM ANALYSIS 74
FIGURE 23 REGENERATIVE MEDICINE MARKET: ECOSYSTEM ANALYSIS 74
TABLE 7 ROLE IN ECOSYSTEM 74
5.8 TECHNOLOGY ANALYSIS 76
FIGURE 24 KEY STEPS IN GENE THERAPY 76
TABLE 8 STEM CELL THERAPIES AND GENE THERAPIES 76
5.9 PATENT ANALYSIS 78
TABLE 9 REGENERATIVE MEDICINE MARKET: INDICATIVE LIST OF PATENTS 79
5.10 KEY CONFERENCES & EVENTS IN 2024–2025 81
5.10.1 REGENERATIVE MEDICINE CONFERENCES IN 2024–2025 81
TABLE 10 REGENERATIVE MEDICINE CONFERENCES IN 2024–2025 81
5.11 TARIFF & REGULATORY LANDSCAPE 82
5.11.1 FDA APPROVALS 82
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83
TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83
TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83
TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85
TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
5.12 PORTER’S FIVE FORCES ANALYSIS 87
TABLE 15 REGENERATIVE MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS 87
5.12.1 THREAT OF NEW ENTRANTS 87
5.12.2 THREAT OF SUBSTITUTES 87
5.12.3 BARGAINING POWER OF BUYERS 88
5.12.4 BARGAINING POWER OF SUPPLIERS 88
5.12.5 DEGREE OF COMPETITION 88
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 89
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 89
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF REGENERATIVE MEDICINE PRODUCTS 89
5.13.2 BUYING CRITERIA FOR REGENERATIVE MEDICINE PRODUCTS 89
FIGURE 26 KEY BUYING CRITERIA FOR END USERS 89
5.14 PIPELINE ANALYSIS 90
TABLE 16 GENE THERAPY PRODUCTS UNDER CLINICAL TRIAL 90
TABLE 17 CELL THERAPY PRODUCTS UNDER CLINICAL TRIAL 93
6 REGENERATIVE MEDICINE MARKET, BY PRODUCT 94
6.1 INTRODUCTION 95
TABLE 18 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 95
6.2 CELL THERAPY 95
TABLE 19 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 96
TABLE 20 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY REGION, 2021–2028 (USD MILLION) 96
TABLE 21 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 22 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 23 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 24 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 98
6.2.1 STEM CELL THERAPY 98
TABLE 25 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 99
TABLE 26 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY REGION, 2021–2028 (USD MILLION) 99
TABLE 27 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 28 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 29 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 30 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 101
6.2.1.1 Cell transplantations 101
6.2.1.1.1 Potential of Allo-SCT in treating AML to drive segmental growth 101
TABLE 31 REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 32 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 33 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 34 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 35 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 104
6.2.1.2 Stem cell therapy products 104
TABLE 36 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 104
TABLE 37 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 105
TABLE 38 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 39 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 40 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 41 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION) 107
6.2.1.2.1 Autologous therapy 107
6.2.1.2.1.1 Low risk of post-treatment complications to support segment growth 107
TABLE 42 REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY REGION, 2021–2028 (USD MILLION) 108
TABLE 43 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 44 EUROPE: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 45 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 46 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 110
6.2.1.2.2 Allogeneic therapy 110
6.2.1.2.2.1 High potential in disease treatment to ensure demand and development 110
TABLE 47 REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 48 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 49 EUROPE: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 50 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 51 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 113
6.2.2 CELL-BASED IMMUNOTHERAPY 113
6.2.2.1 Growing adoption of T-cell therapy in cancer treatment to support market growth 113
TABLE 52 REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY REGION, 2021–2028 (USD MILLION) 114
TABLE 53 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 54 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 55 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 56 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 116
6.3 GENE THERAPY 116
6.3.1 STRONG PRODUCT PIPELINE DUE TO BROADENING APPLICATIONS IN DISEASE TREATMENT TO DRIVE MARKET 116
TABLE 57 APPROVED GENE THERAPIES, 2022 117
TABLE 58 REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY REGION, 2021–2028 (USD MILLION) 117
TABLE 59 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 60 EUROPE: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 61 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 62 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 119
6.4 TISSUE ENGINEERING 119
6.4.1 HIGH DEMAND FOR TISSUE ENGINEERING PRODUCTS IN DERMATOLOGY & WOUND CARE APPLICATIONS TO DRIVE MARKET 119
TABLE 63 REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY REGION, 2021–2028 (USD MILLION) 120
TABLE 64 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 65 EUROPE: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 66 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 67 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION) 122
7 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA 123
7.1 INTRODUCTION 124
TABLE 68 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE PRODUCTS, BY THERAPEUTIC AREA, 2021 VS. 2022 124
TABLE 69 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 125
7.2 ONCOLOGY 125
7.2.1 INCREASING STEM CELL TRANSPLANTS TO DRIVE MARKET 125
TABLE 70 INDICATIVE LIST OF COMMERCIALIZED REGENERATIVE CELL THERAPIES FOR ONCOLOGY APPLICATIONS 126
TABLE 71 REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 128
TABLE 72 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 73 EUROPE: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 74 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 75 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 130
7.3 MUSCULOSKELETAL DISORDERS 130
7.3.1 RISING RESEARCH ON MUSCULOSKELETAL REGENERATION AND PREVALENCE OF ORTHOPEDIC DISORDERS TO DRIVE MARKET 130
TABLE 76 REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 131
TABLE 77 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 78 EUROPE: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 79 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 80 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 133
7.4 DERMATOLOGY & WOUND CARE 133
7.4.1 RISING USE OF WOUND CARE BIOLOGICS TO DRIVE MARKET 133
TABLE 81 INDICATIVE LIST OF REGENERATIVE MEDICINE PRODUCTS COMMERCIALIZED FOR TREATMENT OF ACUTE & CHRONIC WOUNDS 134
TABLE 82 REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY REGION, 2021–2028 (USD MILLION) 134
TABLE 83 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 84 EUROPE: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 85 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 86 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION) 136
7.5 CARDIOVASCULAR DISEASES 136
7.5.1 INCREASING USE OF MSCS FOR CLINICAL RESEARCH ON IHD TO SUPPORT MARKET GROWTH 136
TABLE 87 REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION) 137
TABLE 88 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 89 EUROPE: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 90 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 91 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 139
7.6 OPHTHALMOLOGY 139
7.6.1 REGENERATION OF EYE TISSUES FOR AMD TO SUPPORT MARKET GROWTH 139
TABLE 92 LIST OF PIPELINE PRODUCTS FOR REGENERATIVE MEDICINE IN OPHTHALMOLOGY 140
TABLE 93 REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY REGION, 2021–2028 (USD MILLION) 141
TABLE 94 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 95 EUROPE: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 96 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 97 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 143
7.7 NEUROLOGY 143
7.7.1 GROWING NUMBER OF GENE THERAPY PRODUCTS APPROVED FOR NEUROLOGICAL DISEASE TREATMENT TO DRIVE MARKET GROWTH 143
TABLE 98 REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION) 144
TABLE 99 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 100 EUROPE: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 101 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 102 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 146
7.8 OTHER THERAPEUTIC AREAS 146
TABLE 103 REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION) 147
TABLE 104 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 105 EUROPE: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 148
TABLE 106 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 148
TABLE 107 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 149
8 REGENERATIVE MEDICINE MARKET, BY REGION 150
8.1 INTRODUCTION 151
FIGURE 27 NUMBER OF PLAYERS IN REGENERATIVE MEDICINE MARKET, BY REGION, 2020–2022 151
TABLE 108 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE (2022) 151
TABLE 109 REGENERATIVE MEDICINE MARKET, BY REGION, 2021–2028 (USD MILLION) 152
8.2 NORTH AMERICA 152
FIGURE 28 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT 153
TABLE 110 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 111 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 154
TABLE 112 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 113 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 114 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 115 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 155
8.2.1 US 156
8.2.1.1 Rising number of pipeline products for regenerative medicine to drive market 156
TABLE 116 US: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 157
TABLE 117 US: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 118 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 158
TABLE 119 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 158
TABLE 120 US: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 159
8.2.2 CANADA 159
8.2.2.1 Rising government initiatives for regenerative medicine research to drive market 159
TABLE 121 CANADA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 160
TABLE 122 CANADA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 123 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 124 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 125 CANADA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 162
8.2.3 NORTH AMERICA: RECESSION IMPACT 162
8.3 EUROPE 163
TABLE 126 EUROPE: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 127 EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 164
TABLE 128 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 129 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 130 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 165
TABLE 131 EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 165
8.3.1 GERMANY 166
8.3.1.1 Rising focus on clinical research and patent approvals to drive market 166
TABLE 132 GERMANY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 166
TABLE 133 GERMANY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 167
TABLE 134 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 167
TABLE 135 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 167
TABLE 136 GERMANY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 168
8.3.2 UK 168
8.3.2.1 Incorporating regenerative medicine into commercial healthcare services under NHS to drive market 168
TABLE 137 UK: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 169
TABLE 138 UK: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 169
TABLE 139 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 170
TABLE 140 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 170
TABLE 141 UK: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 171
8.3.3 FRANCE 171
8.3.3.1 Structured regulatory framework to drive regenerative medicine product pipeline 171
TABLE 142 FRANCE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 172
TABLE 143 FRANCE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 144 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 145 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 173
TABLE 146 FRANCE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 173
8.3.4 ITALY 173
8.3.4.1 Rising prevalence of neurological and cardiovascular disorders to drive market 173
TABLE 147 ITALY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 174
TABLE 148 ITALY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 149 ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 150 ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 151 ITALY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 176
8.3.5 SPAIN 176
8.3.5.1 Favorable regulatory environment to drive product pipeline 176
TABLE 152 SPAIN: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 177
TABLE 153 SPAIN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 154 SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 155 SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 156 SPAIN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 179
8.3.6 REST OF EUROPE 179
TABLE 157 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 180
TABLE 158 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 180
TABLE 159 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 180
TABLE 160 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 161 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 181
8.3.7 EUROPE: RECESSION IMPACT 182
8.4 ASIA PACIFIC 182
FIGURE 29 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET SNAPSHOT 183
TABLE 162 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 184
TABLE 163 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 184
TABLE 164 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 185
TABLE 165 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 185
TABLE 166 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 185
TABLE 167 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 186
8.4.1 CHINA 186
8.4.1.1 Favorable government support for development of regenerative medicine to drive market 186
TABLE 168 CHINA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 187
TABLE 169 CHINA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 170 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 188
TABLE 171 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 188
TABLE 172 CHINA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 189
8.4.2 JAPAN 189
8.4.2.1 Regulatory amendments to pharmaceutical legislation to drive commercialization of therapies 189
TABLE 173 JAPAN: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2021–2028 (USD MILLION) 190
TABLE 174 JAPAN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 175 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 176 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 177 JAPAN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,
2021–2028 (USD MILLION) 192
8.4.3 INDIA 192
8.4.3.1 Introduction of novel therapies for CVD and cancer to support market growth 192
TABLE 178 INDIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2021–2028 (USD MILLION) 193
TABLE 179 INDIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 180 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 181 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 194
TABLE 182 INDIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 194
8.4.4 SOUTH KOREA 194
8.4.4.1 Strong research base and availability of funds to support market growth 194
TABLE 183 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 195
TABLE 184 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 185 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 186 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 187 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 197
8.4.5 AUSTRALIA 197
8.4.5.1 Increasing incidence of sports injuries to support market growth 197
TABLE 188 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 198
TABLE 189 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 190 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 191 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 199
TABLE 192 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 199
8.4.6 REST OF ASIA PACIFIC 199
TABLE 193 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 200
TABLE 194 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 200
TABLE 195 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 200
TABLE 196 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 197 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 201
8.4.7 ASIA PACIFIC: RECESSION IMPACT 201
8.5 LATIN AMERICA 202
TABLE 198 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 202
TABLE 199 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 203
TABLE 200 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 203
TABLE 201 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 203
TABLE 202 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 204
TABLE 203 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 204
8.5.1 BRAZIL 204
8.5.1.1 Gradual increase in pharmaceutical R&D to support market growth 204
TABLE 204 BRAZIL: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 205
TABLE 205 BRAZIL: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 206 BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 207 BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 206
TABLE 208 BRAZIL: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 206
8.5.2 REST OF LATIN AMERICA 206
TABLE 209 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 207
TABLE 210 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 207
TABLE 211 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 208
TABLE 212 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 208
TABLE 213 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 209
8.5.3 LATIN AMERICA: RECESSION IMPACT 209
8.6 MIDDLE EAST 210
8.6.1 GROWING FOCUS ON GENETIC MEDICINE DEVELOPMENT PROJECTS TO DRIVE MARKET GROWTH IN COMING YEARS 210
TABLE 214 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2021–2028 (USD MILLION) 210
TABLE 215 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 216 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 217 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 218 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 212
8.6.2 MIDDLE EAST: RECESSION IMPACT 212
8.7 AFRICA 213
8.7.1 GROWING COLLABORATIONS TO SUPPORT GROWTH IN COMING YEARS 213
TABLE 219 AFRICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2021–2028 (USD MILLION) 213
TABLE 220 AFRICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 213
TABLE 221 AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,
BY TYPE, 2021–2028 (USD MILLION) 214
TABLE 222 AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 214
TABLE 223 AFRICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 215
8.7.2 AFRICA: RECESSION IMPACT 215

9 COMPETITIVE LANDSCAPE 216
9.1 INTRODUCTION 216
9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 216
TABLE 224 REGENERATIVE MEDICINE MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 216
9.3 REVENUE SHARE ANALYSIS 219
FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS (2020–2022) 219
9.4 MARKET SHARE ANALYSIS 219
FIGURE 31 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022) 220
TABLE 225 REGENERATIVE MEDICINE MARKET: DEGREE OF COMPETITION 220
9.5 COMPANY EVALUATION MATRIX 221
9.5.1 STARS 222
9.5.2 EMERGING LEADERS 222
9.5.3 PERVASIVE PLAYERS 222
9.5.4 PARTICIPANTS 222
FIGURE 32 REGENERATIVE MEDICINE MARKET: COMPANY EVALUATION MATRIX, 2022 223
9.5.5 COMPANY FOOTPRINT ANALYSIS 224
TABLE 226 REGENERATIVE MEDICINE MARKET: PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS 224
TABLE 227 REGENERATIVE MEDICINE MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS 225
9.6 START-UP/SME EVALUATION MATRIX 226
9.6.1 PROGRESSIVE COMPANIES 226
9.6.2 RESPONSIVE COMPANIES 226
9.6.3 DYNAMIC COMPANIES 226
9.6.4 STARTING BLOCKS 226
FIGURE 33 REGENERATIVE MEDICINE MARKET: START-UP/SME EVALUATION MATRIX, 2022 227
9.6.5 COMPETITIVE BENCHMARKING 228
TABLE 228 REGENERATIVE MEDICINE MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS 228
TABLE 229 REGENERATIVE MEDICINE MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 229
9.7 COMPETITIVE SCENARIO & TRENDS 230
9.7.1 PRODUCT LAUNCHES 230
TABLE 230 REGENERATIVE MEDICINE MARKET: PRODUCT APPROVALS/LAUNCHES, JANUARY 2020 TO DECEMBER 2023 230
9.7.2 DEALS 233
TABLE 231 REGENERATIVE MEDICINE MARKET: DEALS, JANUARY 2020 TO DECEMBER 2023 233
9.7.3 OTHER DEVELOPMENTS 237
TABLE 232 REGENERATIVE MEDICINE MARKET: OTHER DEVELOPMENTS, JANUARY 2020 TO DECEMBER 2023 237
10 COMPANY PROFILES 239
10.1 KEY MARKET PLAYERS 239
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1.1 NOVARTIS AG 239
TABLE 233 NOVARTIS AG: COMPANY OVERVIEW 239
FIGURE 34 NOVARTIS AG: COMPANY SNAPSHOT (2022) 240
10.1.2 BIOGEN INC. 244
TABLE 234 BIOGEN INC.: COMPANY OVERVIEW 244
FIGURE 35 BIOGEN INC.: COMPANY SNAPSHOT (2022) 245
10.1.3 GILEAD SCIENCES, INC. 248
TABLE 235 GILEAD SCIENCES, INC.: COMPANY OVERVIEW 248
FIGURE 36 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022) 249
10.1.4 SAREPTA THERAPEUTICS, INC. 253
TABLE 236 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW 253
FIGURE 37 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2022) 253
10.1.5 AMGEN, INC. 256
TABLE 237 AMGEN, INC.: COMPANY OVERVIEW 256
FIGURE 38 AMGEN, INC.: COMPANY SNAPSHOT (2022) 257
10.1.6 SMITH+NEPHEW 259
TABLE 238 SMITH+NEPHEW: COMPANY OVERVIEW 259
FIGURE 39 SMITH+NEPHEW: COMPANY SNAPSHOT (2022) 260
10.1.7 MEDIPOST CO., LTD. 262
TABLE 239 MEDIPOST CO., LTD.: COMPANY OVERVIEW 262
FIGURE 40 MEDIPOST CO., LTD.: COMPANY SNAPSHOT 262
10.1.8 JCR PHARMACEUTICALS CO., LTD. 265
TABLE 240 JCR PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW 265
FIGURE 41 JCR PHARMACEUTICALS CO., LTD.: COMPANY SNAPSHOT (2022) 265
10.1.9 TAKEDA PHARMACEUTICAL COMPANY LIMITED 267
TABLE 241 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW 267
FIGURE 42 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022) 268
10.1.10 CORESTEM, INC. 270
TABLE 242 CORESTEM, INC.: COMPANY OVERVIEW 270
FIGURE 43 CORESTEM, INC.: COMPANY SNAPSHOT (2021) 270
10.1.11 VERICEL CORPORATION 272
TABLE 243 VERICEL CORPORATION: COMPANY OVERVIEW 272
FIGURE 44 VERICEL CORPORATION: COMPANY SNAPSHOT (2022) 272
10.1.12 MIMEDX GROUP, INC. 274
TABLE 244 MIMEDX GROUP, INC.: COMPANY OVERVIEW 274
FIGURE 45 MIMEDX GROUP, INC.: COMPANY SNAPSHOT (2022) 274
10.1.13 ORGANOGENESIS INC. 278
TABLE 245 ORGANOGENESIS INC.: COMPANY OVERVIEW 278
FIGURE 46 ORGANOGENESIS INC.: COMPANY SNAPSHOT (2022) 278
10.1.14 MEDTRONIC 281
TABLE 246 MEDTRONIC: COMPANY OVERVIEW 281
FIGURE 47 MEDTRONIC: COMPANY SNAPSHOT (2022) 282
10.1.15 BRISTOL-MYERS SQUIBB COMPANY 284
TABLE 247 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW 284
FIGURE 48 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2022) 285
10.2 OTHER PLAYERS 288
10.2.1 ORTHOCELL LTD. 288
TABLE 248 ORTHOCELL LTD.: COMPANY OVERVIEW 288
10.2.2 MESOBLAST LTD. 289
TABLE 249 MESOBLAST LTD.: COMPANY OVERVIEW 289
10.2.3 BIORESTORATIVE THERAPIES, INC. 290
TABLE 250 BIORESTORATIVE THERAPIES, INC.: COMPANY OVERVIEW 290
10.2.4 PLURISTEM THERAPEUTICS INC. 290
TABLE 251 PLURISTEM THERAPEUTICS INC.: COMPANY OVERVIEW 290
10.2.5 TEGOSCIENCE 291
TABLE 252 TEGOSCIENCE: COMPANY OVERVIEW 291
10.2.6 ANTEROGEN.CO.,LTD. 292
TABLE 253 ANTEROGEN.CO.,LTD.: COMPANY OVERVIEW 292
10.2.7 BLUEBIRD BIO, INC. 293
TABLE 254 BLUEBIRD BIO, INC.: COMPANY OVERVIEW 293
10.2.8 STEMPEUTICS RESEARCH PVT. LTD. 294
TABLE 255 STEMPEUTICS RESEARCH PVT. LTD.: COMPANY OVERVIEW 294
10.2.9 SIBIONO GENETECH CO. LTD. 294
TABLE 256 SIBIONO GENETECH CO. LTD.: COMPANY OVERVIEW 294
10.2.10 ASPECT BIOSYSTEMS 295
TABLE 257 ASPECT BIOSYSTEMS: COMPANY OVERVIEW 295
TABLE 258 ATHERSYS, INC.: COMPANY OVERVIEW 296
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX 297
11.1 DISCUSSION GUIDE 297
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 300
11.3 CUSTOMIZATION OPTIONS 302
11.4 RELATED REPORTS 302
11.5 AUTHOR DETAILS 303

★調査レポート[世界の再生医療市場（～2028年）：製品別（幹細胞（自己由来、同種異系）、免疫療法、遺伝子療法、ティッシュエンジニアリング）、用途別（筋骨格系、がん、皮膚科、創傷治療、心血管疾患、眼疾患）] (コード：BT4419-24)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の再生医療市場（～2028年）：製品別（幹細胞（自己由来、同種異系）、免疫療法、遺伝子療法、ティッシュエンジニアリング）、用途別（筋骨格系、がん、皮膚科、創傷治療、心血管疾患、眼疾患）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の再生医療市場（2023-2033)：製品別（細胞治療（自己由来、同種由来）、組織エンジニアリング（足場材、ヒドロゲル）、遺伝子治療、その他）、用途別（腫瘍、皮膚科、筋骨格、神経内科、循環器科、創傷治療、眼科、その他）、地域別
  • 世界のコラーゲン＆ゼラチン市場2023-2033：ソース別（ウシ、ブタ、その他）、用途別（整形外科、創傷治療、歯科、外科、心血管疾患）、エンドユーザー別（病院、外科センター）、地域別（北米、中南米、 ヨーロッパ、アジア太平洋、中東・アフリカ）
  • 世界の再生医療市場（～2027）：製品別（前駆細胞、幹細胞療法、遺伝子治療、その他）、材料別（遺伝子操作材料、合成材料、その他）、用途別（腫瘍、創傷ケア、その他）、エンドユーザー別、地域別
  • 世界の幹細胞療法市場（～2028年）：種類別（同種、自家）、細胞源別（脂肪組織、骨髄、胎盤/臍帯）、治療用途別（筋骨格系、創傷、外科、炎症、自己免疫、心血管）
  • 世界の再生医学(医療)市場2024-2030：製品別（一次細胞系治療薬、幹細胞・前駆細胞系治療薬）、治療カテゴリー別（皮膚科、筋骨格系）、地域別
  • 世界の動物用再生医療市場2022-2029：動物タイプ別（小動物、大動物）、製品別（幹細胞、その他）、用途別（整形外科、外傷＆創傷治療、その他）、エンドユーザー別（動物病院＆クリニック、動物研究機関）、地域別
  • 世界の組織工学市場（～2028年）：製品別（スキャフォールド（コラーゲン、幹細胞）、組織移植片（同種移植片、自家移植片、異種移植片））、材料別（生物学的、合成）、用途別（整形外科、皮膚科、創傷治療、心臓血管）

    • ◆H&Iグローバルリサーチのお客様（例）◆